Canagliflozin
1 paper
- Animals1
Latest
28 in 12 monthsPreprints.org
SGLT2 Inhibitor Adverse Reaction Reporting Relative to Prescribing Volume
Preprint: cross-sectional study of 8,789 peopleSGLT2 inhibitors
Biogerontology
Sex-stratified immune patterns across the canine lifespan and short-term responses to geroprotective interventions
Experiments in 80 dogsBlood and immune system
Metabolites
Plasma as Proxy for Tissue Metabolism When Extending Lifespan in Mice
Experiments in miceInterventions
Frontiers in Endocrinology
Adverse event reporting signals for SGLT-2 inhibitor-metformin combination therapy: a disproportionality analysis of the FAERS database
Computational studySGLT2 inhibitors
Journal of Bone Metabolism
SGLT2 Inhibitors: Dual Effects on Erythropoiesis and Bone Metabolism
ReviewInterventions
Diabetes, Obesity & Metabolism
Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease
Meta-analysis of randomised trialsSGLT2 inhibitors
American Journal of Cardiovascular Drugs
SGLT2 Inhibitors in Cardiovascular-Kidney-Metabolic Syndrome: Drugs Unifying Heart, Kidney, and Metabolism Pharmacotherapy
ReviewSGLT2 inhibitors
bioRxiv
Sex-dimorphic immune trajectories across the canine lifespan and early-life signatures of geroprotective interventions
Preprint: experiments in 80 dogsBlood and immune system
Nephrology, Dialysis, Transplantation
Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial
Randomised trial in 4,401 peopleCanagliflozin